Abstract 1869P
Background
Despite the plethora of patient (pt) communication studies in the past decade, many of them include a diverse and heterogeneous pt and physician cohort. Thus, this single-centre prospective study aimed to measure gastrointestinal (GI) cancer pts' understanding of the information discussed during their first medical oncology visit and their satisfaction with the communication from subspecialized GI medical oncologists.
Methods
Between January and August 2021, chemotherapy-naïve pts in the gastrointestinal clinic at the Princess Margaret Cancer Centre (PMCC), Toronto, Canada, were consecutively approached within 24 hours of their initial consultation to complete a paper-based questionnaire about their understanding of their cancer (diagnosis, treatment plan/intent, prognosis) and satisfaction with the communication. GI medical oncologists concurrently completed a similar questionnaire. Pt and physician responses were compared to assess the degree of concordance. Uni/multivariable analyses were performed to identify pt/physician-based factors associated with concordance levels and pt satisfaction.
Results
A total of 184 matched pt-physician surveys were completed. The concordance rates for understanding of diagnosis, treatment plan, treatment intent, and prognosis were 92.9%, 59.2%, 66.8%, and 59.8%, respectively. Pts who reported treatment intent to be unclear at the time of the consultation were independently associated with lower satisfaction scores compared to those who reported their treatment intent to be curative (p=0.014). There was no statistical significance between patient satisfaction and whether prognosis was disclosed (p=0.08). Table: 1869P
N=184 | Fully concordant, n (%) | Partially concordant, n (%) | Fully discordant, n (%) | Missing, n (%) |
Diagnosis | 171 (92.9) | N/A | 10 (5.4) | 3 (1.6) |
Treatment Plan | 109 (59.2) | 75 (40.8) | 0 (0.0) | 0 (0.0) |
Treatment Intent | 123 (66.8) | N/A | 55 (29.9) | 6 (3.3) |
Prognosis | 110 (59.8) | N/A | 65 (35.3) | 9 (4.9) |
Conclusions
Pt understanding of treatment intent and prognosis after the first medical oncology consultation remain low. Further studies on the effectiveness of consultation aids in this setting are needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Princess Margaret Cancer Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05